Open AccessMolecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Author(s) -
Lisa A. Carey,
Donald A. Berry,
Constance Cirrincione,
William T. Barry,
Brandelyn N. Pitcher,
Lyndsay N. Harris,
David W. Ollila,
Ian E. Krop,
N. Lynn Henry,
Douglas Weckstein,
Carey K. Anders,
Baljit Singh,
Katherine A. Hoadley,
Michael D. Iglesia,
Maggie C.U. Cheang,
Charles M. Perou,
Eric P. Winer,
Clifford A. Hudis
Publication year - 2015
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2015.62.1268
Subject(s) - lapatinib , medicine , trastuzumab , breast cancer , oncology , paclitaxel , neoadjuvant therapy , cancer , cancer research
Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapatinib added to paclitaxel, considering tumor and microenvironment molecular features.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom